SCHEMBL5229299

SCHEMBL5229299

COc1ccc2ccc(O)c(C=O)c2c1

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 7/20 0.57
TRIM24 O15164 1/20 0.53
TYR P14679 1/20 0.53
TRIM33 Q9UPN9 1/20 0.53
MTNR1A P48039 3/20 0.48
MTNR1B P49286 2/20 0.48
MEN1 O00255 1/20 0.47
ALDH1A1 P00352 1/20 0.47
LMNA P02545 1/20 0.47
GAA P10253 1/20 0.47
MAPT P10636 1/20 0.47
KMT2A Q03164 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
MPL P40238 1/20 0.46
RRM1 P23921 1/20 0.46
MAPK1 P28482 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1360246 0.89 ERN1 (0.59) ERN1TRIM24TYRTRIM33
SCHEMBL30066894 0.89 ERN1 (0.59) ERN1TRIM24TYRTRIM33
SCHEMBL5227187 0.81 MTNR1A (0.59) ERN1MTNR1AMTNR1BALDH1A1GAA
SCHEMBL19305505 0.80 ERN1 (0.53) ERN1TRIM24TRIM33ALDH1A1GAA
SCHEMBL16800507 0.78 MTNR1A (0.43) ERN1TRIM24TYRTRIM33MTNR1A
SCHEMBL18156885 0.77 ERN1 (0.59) ERN1
SCHEMBL12674873 0.77 ERN1 (0.47) ERN1
SCHEMBL12674913 0.77 PTPN7 (0.53) ERN1MTNR1AALDH1A1LMNA
SCHEMBL29218980 0.77 MEN1 (0.50) ERN1TRIM24TYRTRIM33MTNR1A
SCHEMBL3906221 0.77 ERN1 (0.63) ERN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115813893-B Application of naphthyl skeleton compound in preparation of coronavirus 3CL protease inhibitor 陕西科技大学 2025-01-28 CN claimed
CN-115813893-A Application of naphthyl skeleton compound in preparing coronavirus 3CL protease inhibitor 陕西科技大学 2023-03-21 CN claimed
CN-119661399-A Synthesis and antibacterial application of novel Schiff base gold (III) compounds 南京中医药大学 2025-03-21 CN disclosed
CN-115813893-B Application of naphthyl skeleton compound in preparation of coronavirus 3CL protease inhibitor 陕西科技大学 2025-01-28 CN disclosed
CN-115813893-A Application of naphthyl skeleton compound in preparing coronavirus 3CL protease inhibitor 陕西科技大学 2023-03-21 CN disclosed
CN-105566276-B Benzo-hexatomic ring derivative as DPP-4 inhibitor and application thereof 华东理工大学 2021-01-08 CN disclosed
EP-3214079-B1 SIX-MEMBERED RING BENZO DERIVATIVES AS DPP-4 INHIBITOR AND USE THEREOF UNIV EAST CHINA SCIENCE & TECH (CN) 2020-06-24 EP disclosed
EP-3214079-B1 SIX-MEMBERED RING BENZO DERIVATIVES AS DPP-4 INHIBITOR AND USE THEREOF UNIV EAST CHINA SCIENCE & TECH (CN) 2020-06-24 EP disclosed
US-10479798-B2 Six-membered ring benzo derivatives as DPP-4 inhibitor and use thereof EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) 2019-11-19 US disclosed
US-10479798-B2 Six-membered ring benzo derivatives as DPP-4 inhibitor and use thereof EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) 2019-11-19 US disclosed
CN-110372663-A Sulfur heterocyclic compound and its application as DPP4 inhibitor derivates 山东百极地长制药有限公司 2019-10-25 CN disclosed
US-20160304429-A1 PROCESS FOR THE SYNTHESIS OF 7-METHOXY-NAPHTHALENE-1-CARBALDEHYDE AND APPLICATION IN THE SYNTHESIS OF AGOMELATINE LES LABORATOIRES SERVIER (FR) 2016-10-20 US disclosed
CN-105793226-A Novel method for the synthesis of 7-methoxy-naphthalene-1-carbaldehyde and use thereof in the synthesis of agomelatine 法国施维雅药厂 2016-07-20 CN disclosed
EP-0998471-B1 SUBSTITUTED HETEROCYCLIC COMPOUNDS, METHOD FOR PREPARING AND COMPOSITIONS CONTAINING SAME SERVIER LAB (FR) 2007-03-14 EP disclosed
US-6602903-B2 Substituted O- and/or S heterocyclic compounds; powerful ligands for melatoninergic receptors. LES LABORATORIES SERVIER (FR) 2003-08-05 US disclosed
US-20020052400-A1 Substituted heterocyclic compounds ADIR ET COMPAGNIE 2002-05-02 US disclosed
US-6313160-B1 FOR THERAPY AND PROPHYLAXIS OF MELATONINERGIC DISORDERS ADIR ET COMPAGNIE (FR) 2001-11-06 US disclosed
EP-0998471-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS, METHOD FOR PREPARING AND COMPOSITIONS CONTAINING SAME ADIR ET COMPAGNIE (FR) 2000-05-10 EP disclosed
WO-1998052935-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS, METHOD FOR PREPARING AND COMPOSITIONS CONTAINING SAME ADIR ET COMPAGNIE (FR) 1998-11-26 WO disclosed
US-4341794-A ANIMAL GROWTH REGULATOR AGENCE NATIONALE DE VALORISATION DE LA RECHERCHE (FR) 1982-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160304429-A1 PROCESS FOR THE SYNTHESIS OF 7-METHOXY-NAPHTHALENE-1-CARBALDEHYDE AND APPLICATION IN THE SYNTHESIS OF AGOMELATINE COMT, TPH1, TPH2 ERN1 2609/4885TRIM24 2216/4885TYR 9/4885
US-10479798-B2 Six-membered ring benzo derivatives as DPP-4 inhibitor and use thereof DPP4, DPP7, DPP3 ERN1 3887/4885TRIM24 2106/4885TYR 802/4885
US-20020052400-A1 Substituted heterocyclic compounds MTNR1A, MTNR1B, CBR1 ERN1 3046/4885TRIM24 3487/4885TYR 355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.